Literature DB >> 24649013

Homology modeling and molecular dynamics studies of Wilms' tumor gene 1 frameshift mutations in exon 7.

Shaoyan Hu1, Ying Wang1, Shuiyan Wu1, Mingying Zhang1, Jian Pan1, Hongjie Shen2, Xiaofei Qi2, Jiannong Cen2, Zixing Chen2, Bairong Shen3, Ruihua Chen4.   

Abstract

As a transcription factor, the Wilms' tumor 1 (WT1) gene plays an important role in leukemogenesis. The impact of WT1 gene mutations has been reported in acute myeloid leukemia (AML). However, the number of available studies on the spatial configuration changes following WT1 mutation is limited. In this study, we sequenced the mutation in exon 7 of the WT1 gene in 60 children with newly diagnosed AML and the spatial configuration of WT1 with frameshift mutations in exon 7 was evaluated using the software for homology modeling and optimization of molecular dynamics. Three cases with frameshift mutations in exon 7 were identified (3/60; mutation rate, 5%). One case had a mutation that had been previously described, whereas the remaining two mutations were first described in our study. Of the three cases, one case presented with antecedent myelodysplastic syndrome (MDS) and the remaining two cases exhibited primary resistance to induction chemotherapy. The spatial configuration analysis demonstrated that the three mutations affected the spatial structure of exon 7 and even affected exon 8 compared to its wild-type. This study demonstrated that the frameshift mutation in exon 7 of the WT1 gene is a poor prognostic factor for children with AML, partly through the spatial configuration changes following frameshift mutations of WT1, which highlights the structure-based function analysis and may facilitate the elucidation of the pathogenesis underlying WT1 gene mutations.

Entities:  

Keywords:  Wilms' tumor gene 1; acute myeloid leukemia; children; frameshift mutation; myelodysplastic syndrome; resistance to chemotherapy

Year:  2013        PMID: 24649013      PMCID: PMC3917735          DOI: 10.3892/br.2013.149

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  19 in total

1.  [Suggestion of diagnosis and treatment of acute myelocytic leukemia in childhood].

Authors: 
Journal:  Zhonghua Er Ke Za Zhi       Date:  2006-11

2.  Structure of the Wilms tumor suppressor protein zinc finger domain bound to DNA.

Authors:  Raphael Stoll; Brian M Lee; Erik W Debler; John H Laity; Ian A Wilson; H Jane Dyson; Peter E Wright
Journal:  J Mol Biol       Date:  2007-07-21       Impact factor: 5.469

3.  Wilms tumor gene (wt1) mRNA is equally expressed in blast cells from acute myeloid leukemia and normal CD34+ progenitors.

Authors:  U Maurer; E Weidmann; T Karakas; D Hoelzer; L Bergmann
Journal:  Blood       Date:  1997-11-15       Impact factor: 22.113

4.  Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Authors:  Heiko Becker; Guido Marcucci; Kati Maharry; Michael D Radmacher; Krzysztof Mrózek; Dean Margeson; Susan P Whitman; Peter Paschka; Kelsi B Holland; Sebastian Schwind; Yue-Zhong Wu; Bayard L Powell; Thomas H Carter; Jonathan E Kolitz; Meir Wetzler; Andrew J Carroll; Maria R Baer; Joseph O Moore; Michael A Caligiuri; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2010-05-04       Impact factor: 22.113

5.  WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system.

Authors:  Hsin-An Hou; Tai-Chung Huang; Liang-In Lin; Chieh-Yu Liu; Chien-Yuan Chen; Wen-Chien Chou; Jih-Luh Tang; Mei-Hsuan Tseng; Chi-Fei Huang; Ying-Chieh Chiang; Fen-Yu Lee; Ming-Chih Liu; Ming Yao; Shang-Yi Huang; Bor-Sheng Ko; Szu-Chun Hsu; Shang-Ju Wu; Woei Tsay; Yao-Chang Chen; Hwei-Fang Tien
Journal:  Blood       Date:  2010-04-05       Impact factor: 22.113

6.  Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.

Authors:  S M Hewitt; S Hamada; T J McDonnell; F J Rauscher; G F Saunders
Journal:  Cancer Res       Date:  1995-11-15       Impact factor: 12.701

Review 7.  A clinical overview of WT1 gene mutations.

Authors:  M Little; C Wells
Journal:  Hum Mutat       Date:  1997       Impact factor: 4.878

8.  Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia.

Authors:  Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Martin Zimmermann; Brian V Balgobind; Susan T C J M Arentsen-Peters; Marielle Alders; Andre Willasch; Gertjan J L Kaspers; Jan Trka; Andre Baruchel; Siebold S N de Graaf; Ursula Creutzig; Rob Pieters; Dirk Reinhardt; C Michel Zwaan
Journal:  Blood       Date:  2009-01-26       Impact factor: 22.113

9.  Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.

Authors:  Verena Ingeborg Gaidzik; Richard Friedrich Schlenk; Simone Moschny; Annegret Becker; Lars Bullinger; Andrea Corbacioglu; Jürgen Krauter; Brigitte Schlegelberger; Arnold Ganser; Hartmut Döhner; Konstanze Döhner
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

10.  Mutations in the Wilms' tumor gene WT1 in leukemias.

Authors:  L King-Underwood; J Renshaw; K Pritchard-Jones
Journal:  Blood       Date:  1996-03-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.